GlassScriptPhysician profile
Jeffrey C Houin
NPI 1972537355
$26,778.81
in general payments reported to CMS, 2019-2025
37 companies · $3,415 in 2025
The $3,415 reported for 2025 was more than what 86% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,991 · 2020: $1,716 · 2021: $2,695 · 2022: $3,335 · 2023: $3,232 · 2024: $3,396 · 2025: $3,415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,488 · Education: $555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,487.59 |
| Education | $555.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $7,086.12 | 2019-2025 | |
| Abbvie INC. | $5,310.82 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $2,446.12 | 2019-2025 | |
| Janssen Biotech, INC. | $2,305.91 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $2,042.06 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Ucb, INC. | $1,155.99 | 2019-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $961.54 | 2019-2025 | Dupixent |
| Lilly USA, LLC | $912.77 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $884.69 | 2019-2025 | |
| Leo Pharma INC. | $693.87 | 2021-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $653.64 | 2022-2025 | Sotyktu |
| Amgen INC. | $365.27 | 2019-2025 | Otezla, Otezla |
| Merz North America, INC. | $236.81 | 2021 | |
| Organon LLC | $169.68 | 2024-2025 | Vtama, Hadlima |
| Galderma Laboratories, L.P. | $162.14 | 2019-2025 | Nemluvio |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $155.01 | 2023-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.93 | 2022-2025 | Spevigo, Cyltezo |
| Kerecis Limited | $133.18 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Mallinckrodt Hospital Products INC. | $122.35 | 2024-2025 | Acthar |
| Organogenesis INC. | $111.71 | 2023-2024 | Puraply |
| Incyte Corporation | $99.46 | 2021-2025 | Opzelura |
| Prugen, INC. Pharmaceuticals | $91.11 | 2019-2020 | |
| Genentech USA, INC. | $76.77 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $70.85 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $58.47 | 2020-2022 | |
| Dermira, INC. | $40.33 | 2019-2020 | |
| Biofrontera INC. | $40.03 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Fresenius Kabi USA, LLC | $39.81 | 2024 | Idacio |
| Dusa Pharmaceuticals, INC. | $31.57 | 2019 | |
| Melinta Therapeutics, LLC | $30.76 | 2019 | |
| Arcutis Biotherapeutics, INC. | $30.73 | 2024 | Zoryve |
| Smith+Nephew, INC. | $22.29 | 2020 | |
| Misonix INC | $21.43 | 2020 | |
| Nabriva Therapeutics, Plc | $18.22 | 2022 | |
| Braeburn INC. | $17.95 | 2025 | Brixadi |
| Sandoz INC. | $13.78 | 2024 | Hyrimoz |
| Merck Sharp & Dohme LLC | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Houin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.